Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 16, 2020 5:27 PM EDT-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million
-GAAP Net Income of $32 Million for Fiscal Year 2019
-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020
-Firdapse Supply Chain in Solid Position-Significant Safety Stock
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 16, 2020 5:26 PM EDT-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million
-GAAP Net Income of $32 Million for Fiscal Year 2019
-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020
-Firdapse Supply Chain in Solid Position-Significant Safety Stock
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More
